TY - JOUR
T1 - 'Working' cardiomyocytes exhibiting plateau action potentials from human placenta-derived extraembryonic mesodermal cells
AU - Okamoto, Kazuma
AU - Miyoshi, Shunichiro
AU - Toyoda, Masashi
AU - Hida, Naoko
AU - Ikegami, Yukinori
AU - Makino, Hatsune
AU - Nishiyama, Nobuhiro
AU - Tsuji, Hiroko
AU - Cui, Chang Hao
AU - Segawa, Kaoru
AU - Uyama, Taro
AU - Kami, Daisuke
AU - Miyado, Kenji
AU - Asada, Hironori
AU - Matsumoto, Kenji
AU - Saito, Hirohisa
AU - Yoshimura, Yasunori
AU - Ogawa, Satoshi
AU - Aeba, Ryo
AU - Yozu, Ryohei
AU - Umezawa, Akihiro
N1 - Funding Information:
We would like to express our sincere thanks to A. Crump for critically reading the manuscript, A. Oka and M. Terai for the support throughout the work, and K. Saito for the secretarial work. This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; by the Suntory Fund for Advanced Cardiac Therapeutics, Keio University School of Medicine; Health and Labor Sciences Research Grants, and the Pharmaceuticals and Medical Devices Agency; by the Research on Health Science Focusing on Drug Innovation from the Japan Health Science Foundation; by the Program for Promotion of Fundamental Studies in Health Science of the Pharmaceuticals and Medical Devices Agency (PMDA); by a research Grant for Cardiovascular Disease from the Ministry of Health, Labor and Welfare; by a Grant for Child Health and Development from the Ministry of Health, Labor and Welfare; and by a grant from Terumo Life Science Foundation. A part of the work was done at the Pfizer Keio Research Laboratory Center for Integrated Medical Research.
PY - 2007/7/15
Y1 - 2007/7/15
N2 - The clinical application of cell transplantation for severe heart failure is a promising strategy to improve impaired cardiac function. Recently, an array of cell types, including bone marrow cells, endothelial progenitors, mesenchymal stem cells, resident cardiac stem cells, and embryonic stem cells, have become important candidates for cell sources for cardiac repair. In the present study, we focused on the placenta as a cell source. Cells from the chorionic plate in the fetal portion of the human placenta were obtained after delivery by the primary culture method, and the cells generated in this study had the Y sex chromosome, indicating that the cells were derived from the fetus. The cells potentially expressed 'working' cardiomyocyte-specific genes such as cardiac myosin heavy chain 7β, atrial myosin light chain, cardiac α-actin by gene chip analysis, and Csx/Nkx2.5, GATA4 by RT-PCR, cardiac troponin-I and connexin 43 by immunohistochemistry. These cells were able to differentiate into cardiomyocytes. Cardiac troponin-I and connexin 43 displayed a discontinuous pattern of localization at intercellular contact sites after cardiomyogenic differentiation, suggesting that the chorionic mesoderm contained a large number of cells with cardiomyogenic potential. The cells began spontaneously beating 3 days after co-cultivation with murine fetal cardiomyocytes and the frequency of beating cells reached a maximum on day 10. The contraction of the cardiomyocytes was rhythmical and synchronous, suggesting the presence of electrical communication between the cells. Placenta-derived human fetal cells may be useful for patients who cannot supply bone marrow cells but want to receive stem cell-based cardiac therapy.
AB - The clinical application of cell transplantation for severe heart failure is a promising strategy to improve impaired cardiac function. Recently, an array of cell types, including bone marrow cells, endothelial progenitors, mesenchymal stem cells, resident cardiac stem cells, and embryonic stem cells, have become important candidates for cell sources for cardiac repair. In the present study, we focused on the placenta as a cell source. Cells from the chorionic plate in the fetal portion of the human placenta were obtained after delivery by the primary culture method, and the cells generated in this study had the Y sex chromosome, indicating that the cells were derived from the fetus. The cells potentially expressed 'working' cardiomyocyte-specific genes such as cardiac myosin heavy chain 7β, atrial myosin light chain, cardiac α-actin by gene chip analysis, and Csx/Nkx2.5, GATA4 by RT-PCR, cardiac troponin-I and connexin 43 by immunohistochemistry. These cells were able to differentiate into cardiomyocytes. Cardiac troponin-I and connexin 43 displayed a discontinuous pattern of localization at intercellular contact sites after cardiomyogenic differentiation, suggesting that the chorionic mesoderm contained a large number of cells with cardiomyogenic potential. The cells began spontaneously beating 3 days after co-cultivation with murine fetal cardiomyocytes and the frequency of beating cells reached a maximum on day 10. The contraction of the cardiomyocytes was rhythmical and synchronous, suggesting the presence of electrical communication between the cells. Placenta-derived human fetal cells may be useful for patients who cannot supply bone marrow cells but want to receive stem cell-based cardiac therapy.
KW - Cardiac differentiation
KW - Co-culture
KW - Placenta
UR - http://www.scopus.com/inward/record.url?scp=34250863867&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34250863867&partnerID=8YFLogxK
U2 - 10.1016/j.yexcr.2007.04.028
DO - 10.1016/j.yexcr.2007.04.028
M3 - Article
C2 - 17544394
AN - SCOPUS:34250863867
SN - 0014-4827
VL - 313
SP - 2550
EP - 2562
JO - Experimental Cell Research
JF - Experimental Cell Research
IS - 12
ER -